Cartesian Therapeutics (RNAC) EBIT Margin: 2015-2025
Historic EBIT Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -4,660.62%.
- Cartesian Therapeutics' EBIT Margin fell 11928.00% to -4,660.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -8,386.53%, marking a year-over-year decrease of 827493.00%. This contributed to the annual value of -112.81% for FY2024, which is 21951.00% up from last year.
- Latest data reveals that Cartesian Therapeutics reported EBIT Margin of -4,660.62% as of Q3 2025, which was up 36.32% from -7,319.13% recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' EBIT Margin registered a high of 3,521.87% during Q4 2024, and its lowest value of -7,319.13% during Q2 2025.
- Moreover, its 3-year median value for EBIT Margin was -355.08% (2023), whereas its average is -1,498.20%.
- As far as peak fluctuations go, Cartesian Therapeutics' EBIT Margin slumped by 798,160bps in 2021, and later spiked by 396,141bps in 2024.
- Quarterly analysis of 5 years shows Cartesian Therapeutics' EBIT Margin stood at 13.62% in 2021, then crashed by 6,421bps to -50.59% in 2022, then tumbled by 38,895bps to -439.54% in 2023, then spiked by 396,141bps to 3,521.87% in 2024, then plummeted by 11,928bps to -4,660.62% in 2025.
- Its EBIT Margin stands at -4,660.62% for Q3 2025, versus -7,319.13% for Q2 2025 and -1,989.91% for Q1 2025.